DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Feagan BG, Sandborn WJ, Danese S. et al
Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
Lancet Gastroenterol Hepatol 2020;
5: 819-828
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.